Virbac Future Growth
Future criteria checks 2/6
Virbac is forecast to grow earnings and revenue by 10.4% and 5.8% per annum respectively. EPS is expected to grow by 10.2% per annum. Return on equity is forecast to be 14.2% in 3 years.
Key information
10.4%
Earnings growth rate
10.2%
EPS growth rate
Pharmaceuticals earnings growth | 16.1% |
Revenue growth rate | 5.8% |
Future return on equity | 14.2% |
Analyst coverage | Good |
Last updated | 20 Sep 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,581 | 185 | 171 | 228 | 6 |
12/31/2025 | 1,496 | 167 | 140 | 202 | 8 |
12/31/2024 | 1,409 | 152 | 82 | 175 | 9 |
6/30/2024 | 1,339 | 141 | 74 | 139 | N/A |
3/31/2024 | 1,293 | 131 | 66 | 129 | N/A |
12/31/2023 | 1,247 | 121 | 59 | 119 | N/A |
9/30/2023 | 1,229 | 120 | 69 | 124 | N/A |
6/30/2023 | 1,210 | 119 | 78 | 129 | N/A |
3/31/2023 | 1,213 | 121 | 62 | 114 | N/A |
12/31/2022 | 1,216 | 122 | 45 | 99 | N/A |
9/30/2022 | 1,184 | 120 | 38 | 91 | N/A |
6/30/2022 | 1,151 | 119 | 31 | 84 | N/A |
3/31/2022 | 1,107 | 116 | 57 | 107 | N/A |
12/31/2021 | 1,064 | 113 | 83 | 130 | N/A |
9/30/2021 | 1,025 | 137 | 80 | 122 | N/A |
6/30/2021 | 985 | 161 | 77 | 113 | N/A |
3/31/2021 | 960 | 148 | 83 | 116 | N/A |
12/31/2020 | 934 | 136 | 90 | 119 | N/A |
9/30/2020 | 944 | 104 | 106 | 133 | N/A |
6/30/2020 | 953 | 72 | 123 | 146 | N/A |
3/31/2020 | 946 | 62 | 116 | 139 | N/A |
12/31/2019 | 938 | 52 | 109 | 132 | N/A |
9/30/2019 | 921 | 43 | 92 | 119 | N/A |
6/30/2019 | 903 | 34 | 76 | 106 | N/A |
3/31/2019 | 886 | 27 | 63 | 95 | N/A |
12/31/2018 | 869 | 20 | 50 | 84 | N/A |
9/30/2018 | 862 | 8 | 58 | 93 | N/A |
6/30/2018 | 854 | -4 | 66 | 103 | N/A |
3/31/2018 | 858 | -3 | N/A | 105 | N/A |
12/31/2017 | 862 | -3 | N/A | 108 | N/A |
9/30/2017 | 871 | 16 | N/A | 112 | N/A |
6/30/2017 | 879 | 35 | N/A | 117 | N/A |
3/31/2017 | 876 | 35 | N/A | 130 | N/A |
12/31/2016 | 872 | 35 | N/A | 142 | N/A |
9/30/2016 | 861 | 30 | N/A | 119 | N/A |
6/30/2016 | 850 | 26 | N/A | 95 | N/A |
3/31/2016 | 851 | 18 | N/A | 71 | N/A |
12/31/2015 | 853 | 9 | N/A | 46 | N/A |
9/30/2015 | 846 | 21 | N/A | 59 | N/A |
6/30/2015 | 839 | 32 | N/A | 72 | N/A |
3/31/2015 | 806 | 48 | N/A | 74 | N/A |
12/31/2014 | 773 | 64 | N/A | 76 | N/A |
9/30/2014 | 752 | 60 | N/A | 77 | N/A |
6/30/2014 | 730 | 56 | N/A | 78 | N/A |
3/31/2014 | 733 | 58 | N/A | 76 | N/A |
12/31/2013 | 736 | 61 | N/A | 74 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0NM7's forecast earnings growth (10.4% per year) is above the savings rate (1.9%).
Earnings vs Market: 0NM7's earnings (10.4% per year) are forecast to grow slower than the UK market (14.2% per year).
High Growth Earnings: 0NM7's earnings are forecast to grow, but not significantly.
Revenue vs Market: 0NM7's revenue (5.8% per year) is forecast to grow faster than the UK market (3.6% per year).
High Growth Revenue: 0NM7's revenue (5.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 0NM7's Return on Equity is forecast to be low in 3 years time (14.2%).